Maruti Suzuki Q3FY25: Maruti Suzuki Reports Record Net Sales and 13% Growth in Vehicle Sales in Q3FY25

Maruti Suzuki Q3FY25 Performance: Record Net Sales and 13% Growth in Vehicle Sales

Maruti Suzuki, India’s leading automobile manufacturer, has announced impressive financial results for the third quarter of FY25 (Q3FY25). The company reported a 13% year-on-year growth in vehicle sales, with total net sales reaching ₹36,802 crore, compared to ₹31,860 crore in the same period last year (Q3FY24).

 

Maruti Suzuki Reports Record Net Sales and 13% Growth in Vehicle Sales in Q3FY25
Maruti Suzuki Reports Record Net Sales and 13% Growth in Vehicle Sales in Q3FY25

 

Key Highlights of Q3FY25:

  1. Total Vehicle Sales: Maruti Suzuki sold 5,66,213 vehicles in Q3FY25, up from 5,01,207 units in Q3FY24.
  2. Domestic Market: The company recorded 4,66,993 vehicle sales in the domestic market, a significant increase from 4,29,422 units in the previous year.
  3. Exports: Maruti Suzuki achieved its highest-ever quarterly exports with 99,220 vehicles, surpassing the 71,785 units exported in Q3FY24.

9MFY25 Performance:

For the nine-month period ending December 2024 (9MFY25), Maruti Suzuki delivered its best-ever performance in terms of sales, net revenue, and profitability.

  • Total Vehicle Sales: The company sold 16,29,631 vehicles, marking a 5% increase compared to 9MFY24.
  • Domestic Sales: 13,82,135 vehicles were sold in the domestic market.
  • Export Sales: 2,47,496 vehicles were exported, showcasing strong global demand.
  • Net Sales: Net revenue stood at ₹1,06,266.4 crore, up from ₹98,240.3 crore in 9MFY24.
  • Net Profit: The company reported a net profit of ₹10,244.1 crore, compared to ₹9,331.6 crore in the same period last year.

Stock Market Update:

On Wednesday, Maruti Suzuki’s shares were trading at ₹12,009.85, down by 0.93%. Despite the slight dip, the company’s strong financial performance and growth trajectory continue to make it a preferred choice for investors.


Cipla Q3FY25 Results: 48.73% Surge in Net Profit

In another significant development, Cipla, a leading pharmaceutical company, reported a 48.73% increase in net profit for Q3FY25. The company’s net profit rose to ₹1,570.51 crore, up from ₹1,055.9 crore in the same quarter last year.

Key Highlights of Cipla’s Q3FY25 Performance:

  • Operating Revenue: Increased to ₹7,072.97 crore from ₹6,603.81 crore year-on-year.
  • Stock Performance: Cipla’s shares reached a 52-week high of ₹1,702 on October 9, 2024. Analysts remain bullish, with target prices ranging from ₹1,550 to ₹1,800.

Brokerage Recommendations:

  • MK Global Financial Services: Target price of ₹1,550.
  • Nuvama: Maintained a “Hold” rating with a target price of ₹1,620.
  • InCred Equities: Upgraded FY25 EPS estimates by 7% and set a target price of ₹1,640.
  • HSBC and Nomura: Recommended a “Buy” with target prices of ₹1,800 and ₹1,780, respectively.